Role of liposomal anthracyclines in breast cancer.

Anthracyclines are among the most effective drugs for patients with breast cancer. Their use, however, has been limited by associated toxic effects, including myelosuppression, alopecia, nausea and vomiting, stomatitis, and most importantly, cardiotoxicity. Liposomal anthracyclines were developed to increase the therapeutic index of conventional anthracyclines by maintaining antitumor efficacy while improving the safety profile. There are currently two liposomal formulations available for treatment of advanced disease: a not pegylated liposomal doxorubicin and a pegylated liposomal doxorubicin. This review will focus on both liposomal formulations of doxorubicin which are approved in Europe and Canada for use in patients with metastatic breast cancer.

[1]  Robin L. Jones,et al.  Anthracycline cardiotoxicity , 2006, Expert opinion on drug safety.

[2]  G. Pond,et al.  Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  G. Batist,et al.  Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis , 2006, Anti-cancer drugs.

[4]  S. Hauptmann,et al.  Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  V. Georgoulias,et al.  Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Chan,et al.  Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  A. Santoro,et al.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  G. Hortobagyi,et al.  Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Wolff.  Liposomal anthracyclines and new treatment approaches for breast cancer. , 2003, The oncologist.

[10]  S. Campos.  Liposomal anthracyclines: adjuvant and neoadjuvant therapy for breast cancer. , 2003, The oncologist.

[11]  H. Gogas,et al.  Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  A. Wolff,et al.  Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Bast,et al.  Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  G. Batist,et al.  Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Nahata,et al.  Cardiotoxicity of Chemotherapeutic Agents , 2000 .

[16]  G. Hortobagyi,et al.  Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Giaccia,et al.  The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. , 1998, Cancer research.

[18]  D. V. Von Hoff,et al.  Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.

[19]  H. von Melchner,et al.  Adriamycin cardiotoxicity: a survey of 1273 patients. , 1979, Cancer treatment reports.

[20]  J. Mason,et al.  Anthracycline cardiomyopathy monitored by morphologic changes. , 1978, Cancer treatment reports.

[21]  I. Ifrim,et al.  Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. , 1977, Science.

[22]  Lyndsay Harris,et al.  Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma , 2002, Cancer.

[23]  Kathy Wilkinson,et al.  Liposomal doxorubicin. , 2002, Clinical journal of oncology nursing.

[24]  M. Bally,et al.  A Comparison of Liposomal Formulations of Doxorubicin with Drug Administered in Free Form , 2001, Drug safety.

[25]  M. Nahata,et al.  Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. , 2000, Drug safety.